ABOUT DNX
DNX is a biopharmaceutical company developing long-acting therapeutic
proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is
pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation,
which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related
to the PASylation technology to develop and commercialize several PASylated products.
DNX aims to develop its lead product (DNX-114) as the first, 2nd generation long-acting, high-affinity soluble TNF receptor
antagonist using PASylation, for the treatment of rheumatoid arthritis and other related diseases, while off-setting the development cost through
corporate deals involving company-specific target drug selection (e.g. DNX-214|314|414|514) for half-life modification and
for favorably prolonging the long-term fade-rates of those product franchises.
BUSINESS FOCUS
Making Good Drugs Great. To build a Biopharmaceutical company by taking select biological drugs or their biosimilars and developing long-acting versions of those products.
Such novel versions of innovator drugs, whose performance has been enhanced by modifications to the initial product, is expected to have
improved clinical performance, increased patient compliance and reduced treatment costs.
BUSINESS STRATEGY
DNX's business strategy is to develop better biopharmaceuticals - novel versions of marketed biologics whose performance can be enhanced by modifications
to the initial product, which improve clinical performance, prolong half-life, increase patient compliance and reduce overall treatment costs,
without increasing the cost-of-goods (COGS) factor.
Without taking on the excessive risk associated with identifying novel targets or creating new classes of drugs, DNX aims to create
improved versions of well-established biopharmaceuticals, which can generate above average returns. DNX either owns the Intellectual
Property (IP) or has negotiated access to such products.
Consistent with the approach of a number of successful companies in our industry, DNX is committed to creating a low-overhead,
semi-virtual operating environment that will not saddle DNX with high fixed costs. Instead, DNX will take advantage of a vast
reservoir of talent, consisting of experienced biopharmaceutical professionals to work on a project basis. In other words, DNX
will aim to function as a protean corporation.
